Amyloidosis is an underdiagnosed, progressive group of diseases characterized by the abnormal buildup of a protein called ...

Editas' share price has struggled due to clinical setbacks, but recent focus on in-vivo gene editing offers renewed hope and ...

The latest update is out from Prothena ( (PRTA) ).

Precision medicine promises to tailor health care to the individual. But what happens when entire communities are left out of ...

Akero Therapeutics Inc. (NASDAQ: AKRO) is one of the best mid cap pharma stocks to buy. On July 16, AstraZeneca announced ...

Topline data were announced from a phase 3 clinical program evaluating anselamimab in patients with Mayo stages 3a and 3b light chain (AL) amyloidosis.

Return on Assets (ROA): Ionis Pharmaceuticals's ROA lags behind industry averages, suggesting challenges in maximizing ...

Some genetically targeted therapies are classified in the IRA as small-molecule drugs, limiting the incentive for biotech ...

This month: good news for java lovers, a how-to guide on migraine and CVD, medically tailored meals for HF, and more.

Here are five high-yield dividend stocks that offer passive income and solid entry points that investors can buy and forget ...

These five blue-chip dividend stocks have had a tough 2025 but are solid long-term buys for growth and income investors.

We recently compiled a list of 10 Most Undervalued Healthcare Stocks to Buy According to Analysts. Alnylam Pharmaceuticals, ...